What You'll Learn
Table of Contents
Blood Sugar and Type 2 Diabetes
This is where the drug class started, and remains its best-established use: the first GLP-1 receptor agonist was approved for type 2 diabetes in 2005, well before any weight-management indication existed. Blood-sugar control via enhanced, glucose-dependent insulin release is the original, most extensively studied effect of this mechanism. See our guide to what GLP-1 medications are for the full mechanism. The compounds still in development are covered separately in the peptide research section.
Cardiovascular Risk: The SELECT Trial
In adults 45+ with pre-existing cardiovascular disease and a BMI of 27 or greater but no history of diabetes, weekly semaglutide 2.4mg was superior to placebo on a composite endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke: 6.5% versus 8.0% over a mean 39.8 months. This is the pivotal citation for this entire article: it moved GLP-1 therapy from "a weight and blood-sugar drug" to a drug class with a demonstrated hard cardiovascular-outcome benefit, independent of a diabetes diagnosis.
PMID: 37952131 ↗That's a materially stronger evidence claim than weight loss alone — hard clinical outcomes, not a surrogate marker like weight or blood sugar. But the size of it is routinely misread: a 20% relative reduction here is a 1.5-percentage-point absolute one, in people who had already had a cardiovascular event. The full reading of the SELECT trial — including the discontinuation rate reported in the same paper.
Fatty Liver Disease
This has moved well past markers. In the ESSENCE phase 3 trial, weekly semaglutide resolved steatohepatitis on repeat biopsy in 62.9% of patients with confirmed MASH and moderate-to-advanced fibrosis — against 34.3% on placebo. Both figures are worth reading: the drug roughly doubled the resolution rate, and a third of the placebo group got there anyway. The full reading of ESSENCE — and why an incidental fatty liver note on a scan is a different situation entirely.
Sleep Apnea
Weight loss is a well-established lever for reducing obstructive sleep apnea severity across any weight-loss method. The evidence here is now stronger than that general statement: two randomised, double-blind, placebo-controlled trials in 469 adults found apnea events falling by 20 to 24 per hour more than placebo. The full breakdown of what those trials found — including why nobody in them was told to stop using CPAP.
Blood Pressure
Blood pressure reductions are commonly observed across GLP-1 trials, generally attributed to weight loss itself rather than a distinct, independent antihypertensive mechanism of the drug. This doesn't make the effect less real — it just means the likely pathway runs through weight loss, the same as with most other weight-loss interventions.
Putting It Together
| Condition | What the evidence shows | Evidence strength |
|---|---|---|
| Type 2 diabetes | Original, best-established use of this drug class | Strong |
| Cardiovascular death risk | Reduced in the SELECT RCT, independent of diabetes status | Strong |
| Fatty liver disease | Improving markers, likely downstream of weight loss | Moderate |
| Sleep apnea | Improvement consistent with weight-loss mechanism generally | Moderate |
| Blood pressure | Reduced, likely via weight loss rather than a distinct mechanism | Moderate |
Bottom line: The metabolic-health case for GLP-1 therapy is genuinely broader than weight loss alone — but each downstream benefit deserves its own evidence grade, not a halo borrowed from the SELECT trial's strong cardiovascular result.
